Johnson & Johnson (JNJ) EBITDA (2009 - 2026)
Johnson & Johnson (JNJ) posted EBITDA of $7.1 billion for Q2 2026, up 12.21% sequentially from $6.4 billion in Q1 2026, and up 7.43% YoY from $6.6 billion in Q2 2025.
Johnson & Johnson (JNJ) EBITDA (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported EBITDA for 18 years, with the latest figure at $7.1 billion in Q2 2026.
- Quarterly EBITDA rose 7.43% year-over-year to $7.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $26.0 billion (up 21.33% YoY) and the FY2025 annual result came in at $25.4 billion, up 20.71% from the prior year.
- EBITDA advanced to $7.1 billion in Q2 2026 per JNJ's latest filing, from $6.4 billion in the prior quarter.
- Over five years, EBITDA peaked at $9.6 billion in Q1 2023 and troughed at $3.6 billion in Q4 2024.
- A 5-year average of $5.8 billion and a median of $5.8 billion in 2023 frame the typical range for EBITDA.
- The sharpest annual moves came in 2023 and 2025: EBITDA tumbled 55.76% in 2023, then surged 53.01% in 2025.
- Over 5 years, EBITDA stood at $5.3 billion in 2022, then slipped by 19.78% to $4.3 billion in 2023, then declined by 15.34% to $3.6 billion in 2024, then soared by 53.01% to $5.5 billion in 2025, then increased by 29.65% to $7.1 billion in 2026.
- According to Business Quant data, EBITDA over the past three periods registered $7.1 billion, $6.4 billion, and $5.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 7.14 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 6.43 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -584.00 Mn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 4.75 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 3.16 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 3.51 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -10.39 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 4.27 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 645.35 Mn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 16.77 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 7.14 Bn |
| Mar 29, 2026 | 6.36 Bn |
| Dec 28, 2025 | 5.51 Bn |
| Sep 28, 2025 | 7.03 Bn |
| Jun 29, 2025 | 6.65 Bn |
| Mar 30, 2025 | 6.18 Bn |
| Dec 29, 2024 | 3.60 Bn |
| Sep 29, 2024 | 5.04 Bn |
| Jun 30, 2024 | 6.47 Bn |
| Mar 31, 2024 | 5.91 Bn |
| Dec 31, 2023 | 4.25 Bn |
| Oct 1, 2023 | 5.74 Bn |
| Jul 2, 2023 | 5.81 Bn |
| Apr 2, 2023 | 5.72 Bn |
| Jan 1, 2023 | 9.61 Bn |
| Oct 2, 2022 | 5.30 Bn |
| Jul 3, 2022 | 3.88 Bn |
| Apr 3, 2022 | 4.35 Bn |
| Oct 3, 2021 | 6.61 Bn |
| Jul 4, 2021 | 6.20 Bn |